Compare · ABT vs ENSC
ABT vs ENSC
Side-by-side comparison of Abbott Laboratories (ABT) and Ensysce Biosciences Inc. (ENSC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ENSC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $153.59B, about 39792.8x ENSC ($3.9M).
- Over the past year, ABT is down 35.0% and ENSC is down 88.2% - ABT leads by 53.1 points.
- ABT has been more active in the news (7 items in the past 4 weeks vs 2 for ENSC).
- ABT has more recent analyst coverage (25 ratings vs 1 for ENSC).
- Company
- Abbott Laboratories
- Ensysce Biosciences Inc.
- Price
- $88.09-1.73%
- $0.25-3.36%
- Market cap
- $153.59B
- $3.9M
- 1M return
- +5.08%
- -11.76%
- 1Y return
- -35.03%
- -88.18%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 2
- Recent ratings
- 25
- 1
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Ensysce Biosciences Inc.
Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is headquartered in La Jolla, California.
Latest ABT
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
Latest ENSC
- SEC Form S-3 filed by Ensysce Biosciences Inc.
- Ensysce Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Ensysce Biosciences Reports First Quarter 2026 Financial Results
- Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
- Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
- SEC Form S-8 filed by Ensysce Biosciences Inc.
- Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
- SEC Form EFFECT filed by Ensysce Biosciences Inc.
- SEC Form S-3 filed by Ensysce Biosciences Inc.
- Ensysce Biosciences Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits